# Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases

> **NCT01151644** · PHASE4 · UNKNOWN · sponsor: **University of Sao Paulo** · enrollment: 5000 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Spondyloarthritis
- Systemic Lupus Erythematosus (SLE)
- Dermatomyositis (DM)
- DMixed Connective Tissue Disease
- Systemic Vasculitis
- Systemic Sclerosis (SSc)
- Sjögren's Syndrome
- Antiphospholipid Syndrome
- Juvenile Idiopathic Arthritis
- Juvenile SLE
- Juvenile DM

## Interventions

- **BIOLOGICAL:** Anti-pandemic H1N1 influenza vaccine

## Key facts

- **NCT ID:** NCT01151644
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-04
- **Primary completion:** 2010-07
- **Final completion:** 2010-12
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2010-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01151644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01151644, "Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01151644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*